MoCD Type A is a rapidly progressive autosomal recessive inborn error of metabolism
How we are supporting with uninterrupted supply of medicines for clinical trials
- by Inceptua
- | March 22, 2020
In clinical trials, a Comparator drug, either an investigational or marketed product, is often required to determine the efficacy relative to a drug that is already on the market. Safe, Reliable and Timely Supply of Comparator Drugs is critical to assuring these clinical trials are uninterrupted, protocols are not deviated, and patients continue with their treatments.
To support our customers and the global community of Pharmaceutical and Clinical Research Organizations supporting life-saving clinical trials, Inceptua has formed a Rapid Response Team of industry-leading experts in Supply Chain, Quality, Regulatory and Procurement that can guide you through COVID19 and the changing global Comparator procurement landscape.
How can we help prevent disruption to your clinical trials?
Use the below contact form to get support from our Response Team.
Heather Manna, VP, Global Regulatory Affairs, Inceptua Early Access, answers questions about Real World Data and Early Access.
Apealea is the first Cremophor-free formulation of paclitaxel approved in combination with carboplatin for ovarian cancer.